Navigation Links
Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
Date:5/10/2013

NSI-566, was approved by the FDA to commence a Phase I trial to treat chronic spinal cord injury (cSI). This open-label, multi-site study will enroll up to eight patients with thoracic spinal cord injuries (T2-T12) who have an American Spinal Injury Association AIS-A level of impairment, between one and two years post injury. These patients exhibit no motor or sensory function in the relevant segments at and below the injury, and are considered to be in complete paralysis. Study patients will receive six injections in, or around, the injury site: the first four patients will receive 100,000 cells per injection; the second four patients, 200,000 cells per injection. All NSI-566/cSCI patients will receive post-surgery physical therapy, as well as immunosuppressive therapy, which will be for three months, as tolerated. The trial study period will end six months post-surgery for each patient. The primary objective of the study is to determine the safety and toxicity of NSI-566 for the treatment of paralysis and related symptoms due to cSCI. The secondary objectives are to evaluate graft survival in the transplant site by MRI, as well as the effectiveness of transient immunosuppression.

In January, Neuralstem received issuance of U.S. Patent #8,362,262, Divisional Compositions and Methods of Use, part of the small molecule IP; additionally, issuance of PCT Patent #2337517, Floating Cannula and Method of Use, which is exclusively licensed by Neuralstem, and validated in four European countries: Germany, France, Italy and United Kingdom, for a total of five European patents.

In February, Neuralstem's NSI-566 Phase I Clinical Trial in ALS (amyotrophic lateral sclerosis, or Lou Gehrig 's disease) officially concluded, six months after the final surgery at Emory University Hospital.

In February, Neuralstem granted li
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
2. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
3. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
4. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
5. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
6. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
7. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
8. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
9. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
10. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
11. Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... SUMMERLAND, British Columbia , Feb. 27, 2015 ... ), a leader in synthetic biology, today announced it ... Fruits (OSF), the pioneering agricultural company behind the ... non-browning apple. Through the acquisition, Intrexon expands its food ... appetizing and convenient for consumers while providing economic benefit ...
(Date:2/27/2015)... Immunovaccine Inc. (“Immunovaccine”) (TSX: IMV), ... announced that the U.S. Food and Drug Administration ... and Phase I clinical trials of the DPX-Anthrax ... co-development agreement signed with Gilead Life Sciences. The ... the DPX-Survivac. , “We have been in talks ...
(Date:2/27/2015)... February 27, 2015 FamilyFarms Group is ... Manager of State Line Farms, received the 2015 Tomorrow’s ... producer, under the age of 35, who has demonstrated ... an honor to win the Tomorrow's Top Producer Horizon ... won the Top Producer Award and learning from their ...
(Date:2/26/2015)... NEW YORK , Feb. 26, 2015 ... commenced Factual Stock Report coverage on MabVax Therapeutics ... Inc. (MBVX) is a clinical stage biotechnology company focused ... address unmet medical needs in the treatment of cancer. ... products based on the protective immune responses generated by ...
Breaking Biology Technology:Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5
... Boston Scientific Corporation (NYSE: BSX ) ... ® Clinical Science program, which demonstrated that defibrillator ... in mortality due to defibrillator shock.  Instead, the authors ... is not attributed to the defibrillator shock itself, but ...
... May 5, 2011 Momentum is building ... (ErgoExpo), the largest ergonomics event in the nation, held ... 2, 2011. The expo has already grown over 10% ... and exhibitors increasing the size of their exhibit space. ...
... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... commercialization of products for central nervous system disorders, today ... ended March 31, 2011. "We are very ... date in 2011," said Mihael H. Polymeropoulos, M.D., President ...
Cached Biology Technology:ALTITUDE Clinical Data Show ICD Therapy Saves Lives Without Mortality Increase from Device Shock 2ALTITUDE Clinical Data Show ICD Therapy Saves Lives Without Mortality Increase from Device Shock 3ALTITUDE Clinical Data Show ICD Therapy Saves Lives Without Mortality Increase from Device Shock 42011 National Ergonomics Conference and Expo (ErgoExpo) Announces HP, CDC, VPPPA Leaders to Keynote; Expo on Pace to Sell Out 2Vanda Pharmaceuticals Reports First Quarter 2011 Results 2Vanda Pharmaceuticals Reports First Quarter 2011 Results 3Vanda Pharmaceuticals Reports First Quarter 2011 Results 4Vanda Pharmaceuticals Reports First Quarter 2011 Results 5Vanda Pharmaceuticals Reports First Quarter 2011 Results 6Vanda Pharmaceuticals Reports First Quarter 2011 Results 7Vanda Pharmaceuticals Reports First Quarter 2011 Results 8
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the ... report to their offering. , The ... individual is who she/he is claiming to be, and for ... unique physical characteristics, such as fingerprint, hand or palm print, ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
(Date:1/22/2015)... 2015 Technology Showcase, Hall E -   EyeLock Inc. ... announced it will showcase its EyeLock ID technology integrated in ... of Energy,s Oak Ridge National Laboratory (ORNL) at ... iris identity authentication technology is being used to validate the ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... WASHINGTON (20 April 2010) -- Ultrasound pioneer Gerald J. ... the highest award in the engineering profession on ... (AAES). Posakony,s pioneering contributions to the fields ... were recognized during AAES, 31st annual awards ceremony at ...
... today new study results showing that when and how ... life has vital implications to a child,s developmental, diagnostic, ... Journal of Autism and Developmental Disorders (Epub ahead ... warning signs may actually be at lower risk for ...
... Researchers have made an important breakthrough in the use of ... cells an innovative technology that could significantly reduce the ... The advance was just reported in Current Applied Physics ... and Yeungnam University in Korea. This is one of ...
Cached Biology News:Ultrasound pioneer receives highest award in engineering profession 2Ultrasound pioneer receives highest award in engineering profession 3Ultrasound pioneer receives highest award in engineering profession 4Ultrasound pioneer receives highest award in engineering profession 5Ultrasound pioneer receives highest award in engineering profession 6Study provides new insights into the implications of autism onset patterns 2Study provides new insights into the implications of autism onset patterns 3Advance made in thin-film solar cell technology 2Advance made in thin-film solar cell technology 3
BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....
The F40 piston assembly is supplied as two assemblies to service one F40 pump of a BioLogic DuoFlow workstation....
... used as an internal standard for the ... mass spectrometry. 5-OxoETE is a polyunsaturated keto ... in human neutrophils. It stimulates cytosolic calcium ... 2 nM. 5-OxoETE selectively stimulates the migration ...
...
Biology Products: